The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2022 | Reassessing free light chain criteria used in the diagnosis of MM

Name: Reassessing free light chain criteria used in the diagnosis of MM
Uploaded: 2022-06-14T00:00:00Z
Duration: 1 min 27 s
Description: In this study, Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, highlights a study which investigated the free light chain criteria used in the 2014 IMWG diagnostic criteria, and implications of this study in the future treatment of multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Malin Hultcrantz • 14 Jun 2022

EHA 2022

Multiple Myeloma Rare Diseases Smoldering Myeloma

In this study, Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, highlights a study which investigated the free light chain criteria used in the 2014 IMWG diagnostic criteria, and implications of this study in the future treatment of multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research Funding: GSK, Amgen, Daiichi Sankyo, Cosette
Advisory board: BMS
Consultancy: Curio Science LLC, Intellisphere LLC
Membership on an entity’s Board of Directors or advisory committees: GSK